Fiche publication
Date publication
avril 2020
Journal
Pharmacology & therapeutics
Auteurs
Membres identifiés du Cancéropôle Est :
Pr GENY Bernard
Tous les auteurs :
Lugnier C, Meyer A, Talha S, Geny B
Lien Pubmed
Résumé
Metabolic diseases have a tremendous impact on human morbidity and mortality. Numerous targets regulating adenosine monophosphate kinase (AMPK) have been identified for treating the metabolic syndrome (MetS), and many compounds are being used or developed to increase AMPK activity. In parallel, the cyclic nucleotide phosphodiesterase families (PDEs) have emerged as new therapeutic targets in cardiovascular diseases, as well as in non-resolved pathologies. Since some PDE subfamilies inactivate cAMP into 5'-AMP, while the beneficial effects in MetS are related to 5'-AMP-dependent activation of AMPK, an analysis of the various controversial relationships between PDEs and AMPK in MetS appears interesting. The present review will describe the various PDE families, AMPK and molecular mechanisms in the MetS and discuss the PDEs/PDE modulators related to the tissues involved, thus supporting the discovery of original molecules and the design of new therapeutic approaches in MetS.
Mots clés
Cyclic nucleotide phosphodiesterase (PDE), PDE inhibitor, adenosine monophosphate kinase (AMPK), cAMP (cyclic AMP), cGMP (cyclic GMP), metabolic syndrome (MetS)
Référence
Pharmacol Ther. 2020 04;208:107475
